Screener
Allogene Therapeutics ALLO Income Tax
Discontinued — last reported Q4 '25
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Allogene Therapeutics’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017242
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Other income (expense), net | 215 | (3,920) |
| Total other income (expense), net | 18,429 | 16,052 |
| Loss before income taxes | (190,886) | (257,147) |
| Income tax expense | — | (443) |
| Net loss | (190,886) | (257,590) |
| Other comprehensive loss: | ||
| Net unrealized gain on available-for-sale investments | 358 | 866 |
| Net comprehensive loss | $(190,528) | $(256,724) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Allogene Therapeutics's income tax?
- Allogene Therapeutics (ALLO) reported income tax of $0 in Q4 2025.
- How has Allogene Therapeutics's income tax changed year-over-year?
- Allogene Therapeutics's income tax decreased by 100.0% year-over-year, from $110.75K to $0.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Allogene Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude